Management of recurrent ventricular tachyarrhythmias associated with Q-T prolongation.
Eleven patients with acquired prolongation of the Q-Tc interval and recurrent ventricular tachyarrhythmias were studied. Five patients required 5 to 44 direct current shocks to correct prolonged ventricular tachyarrhythmias, and five were given at least two antiarrhythmic agents in an attempt to control the arrhythmias. In 4 of the 11 patients, when thioridazine, diuretic drugs and antiarrhythmic agents were withdrawn and hypokalemia or hypocalcemia corrected, ventricular tachyarrhythmias did not recur. The Q-Tc interval normalized in 2 to 3 days. Ventricular tachyarrhythmias were recurrent in the remaining seven patients, despite withdrawal of the drugs that caused the Q-Tc prolongation, attempted correction of hypokalemia when present and the administration of antiarrhythmic agents to four of the seven. All antiarrhythmic agents were then withdrawn in this group. Immediately on the establishment of overdrive ventricular or atrioventricular sequential pacing in these patients, ventricular tachyarrhythmias were abolished. No breakthrough ventricular tachyarrhythmias occurred during temporary pacing. Temporary pacing was required for an average of 10 days and the Q-Tc interval normalized an average of 5 days from the onset of pacing. Three patients required a permanent pacemaker, one because of chronic complete heart block, one because of the sick sinus syndrome, and one because of frequent ventricular ectopic complexes complicating ischemic heart disease. All 11 patients survived their period of hospitalization.
D000328:Adult; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000188:drug therapy / Q000628:therapy*; D002125:Calcium Gluconate / Q000627:therapeutic use; D002304:Cardiac Pacing, Artificial; D002762:Cholecalciferol / Q000627:therapeutic use; D004562:Electrocardiography; D005260:Female; D005665:Furosemide / Q000627:therapeutic use; D006327:Heart Block / Q000628:therapy; D006801:Humans; D007008:Hypokalemia / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D013881:Thioridazine / Q000627:therapeutic use
D000889:Anti-Arrhythmia Agents; D002762:Cholecalciferol; D005665:Furosemide; D013881:Thioridazine; D002125:Calcium Gluconate